Dashboard
Manage Tickers

AGENAGENUS INC

Nasdaq agenusbio.com


$ 5.14 $ 0.18 (3.64 %)    

Monday, 09-Sep-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 5.13
$ 5.12 x 100
$ 5.14 x 100
-- - --
$ 4.41 - $ 27.20
288,310
na
110.66M
$ 1.72
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 03-14-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-16-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-01-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-07-2021 03-31-2021 10-Q
15 03-16-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-16-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-09-2019 06-30-2019 10-Q
22 05-10-2019 03-31-2019 10-Q
23 03-18-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-16-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-07-2017 06-30-2017 10-Q
30 05-04-2017 03-31-2017 10-Q
31 03-16-2017 12-31-2016 10-K
32 11-09-2016 09-30-2016 10-Q
33 08-04-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 03-15-2016 12-31-2015 10-K
36 11-04-2015 09-30-2015 10-Q
37 08-03-2015 06-30-2015 10-Q
38 05-01-2015 03-31-2015 10-Q
39 03-16-2015 12-31-2014 10-K
40 10-31-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

agenus-to-present-cancer-therapy-data-for-refractory-sarcomas-at-esmo-2024
Agenus to Present Cancer Therapy Data for ...
09/09/2024 11:32:17

Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today...

b-riley-securities-maintains-buy-on-agenus-lowers-price-target-to-18
B. Riley Securities Maintains Buy on Agenu...
08/14/2024 12:58:24

B. Riley Securities analyst Yuan Zhi maintains Agenus (NASDAQ:AGEN) with a Buy and lowers the price target from $42 to $18.

agenus-q2-2024-gaap-eps-252-misses-107-estimate-sales-23509m-miss-61477m-estimate
Agenus Q2 2024 GAAP EPS $(2.52) Misses $(1...
08/08/2024 11:19:42

Agenus (NASDAQ:AGEN) reported quarterly losses of $(2.52) per share which missed the analyst consensus estimate of $(1.07) by 1...

agenus-publishes-seminal-study-in-cancer-discovery-detailing-novel-mechanism-and-effectiveness-of-botensilimab-in-treatment-resistant-cancers
Agenus Publishes Seminal Study In Cancer D...
08/07/2024 15:03:06

Antibody, Is Effective Against Tumors Poorly Responsive to Conventional Immunotherapy," highlights several key findings:Dem...

bristol-myers-squibb-terminates-cancer-drug-development-program-with-agenus
Bristol Myers Squibb Terminates Cancer Dru...
08/05/2024 18:31:11

Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AG...

jefferies-downgrades-agenus-to-hold-raises-price-target-to-7
Jefferies Downgrades Agenus to Hold, Raise...
07/19/2024 21:16:27

Jefferies analyst Biren Amin downgrades Agenus (NASDAQ:AGEN) from Buy to Hold and raises the price target from $3 to $7.

agenus-faces-regulatory-and-financial-challenges-analyst-downgrades-stock-pending-trial-clarity
Agenus Faces Regulatory and Financial Chal...
07/19/2024 17:00:21

Agenus faces a setback as the FDA advises against accelerated approval for its immunotherapy combination, botensilimab and bals...

nasdaq-down-over-100-points-abbott-laboratories-earnings-beat-views
Nasdaq Down Over 100 Points; Abbott Labora...
07/18/2024 18:31:40

why-dominos-pizza-shares-are-trading-lower-by-over-11-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Domino's Pizza Shares Are Trading Lowe...
07/18/2024 17:19:11

hc-wainwright--co-downgrades-agenus-to-neutral-lowers-price-target-to-9
HC Wainwright & Co. Downgrades Agenus to N...
07/18/2024 16:38:01

HC Wainwright & Co. analyst Emily Bodnar downgrades Agenus (NASDAQ:AGEN) from Buy to Neutral and lowers the price target...

dow-dips-250-points-us-weekly-jobless-claims-surge
Dow Dips 250 Points; US Weekly Jobless Cla...
07/18/2024 16:06:35

agenus-loses-more-than-50-value-on-thursday---heres-why
Agenus Loses More Than 50% Value On Thursd...
07/18/2024 15:47:55

Agenus shares drop amid FDA's feedback on its immunotherapy combo botensilimab and balstilimab for colorectal cancer. The F...

us-stocks-edge-higher-dr-horton-posts-upbeat-earnings
US Stocks Edge Higher; D.R. Horton Posts U...
07/18/2024 14:04:45

Core News & Articles
Market-Moving News for July 18th
07/18/2024 12:28:09

NKGN: 88% | NKGen Biotech Will Present New Biomarker Data On SNK01 In Alzheimer's Disease During A Poster Presentation At T...

agenus-announces-end-of-phase-2-meeting-outcomes-announces-topline-interim-phase-2-data-for-botbal-agreement-reached-with-fda-on-phase-3-dose-for-botbal-combination
Agenus Announces End-of-Phase-2 Meeting Ou...
07/18/2024 11:07:22

hc-wainwright--co-reiterates-buy-on-agenus-maintains-40-price-target
HC Wainwright & Co. Reiterates Buy on Agen...
06/28/2024 17:30:55

HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:AGEN) with a Buy and maintains $40 price target.

agenus-announces-extended-botbal-therapy-yields-pronounced-tumor-reductions-in-colon-cancer-results-from-investigator-sponsored-trial-presented-at-2024-esmo-gastrointestinal-cancers-congress
Agenus Announces Extended BOT/BAL Therapy ...
06/28/2024 15:10:35

agenus-says-cancer-therapy-evaluation-program-is-accepting-lois-to-conduct-clinical-studies-using-botensilimab-which-is-being-developed-by-ctep-as-an-anticancer-agent-in-collaboration-with-company
Agenus Says Cancer Therapy Evaluation Prog...
06/27/2024 11:35:04

Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today...

agenus-reports-potential-new-treatment-for-colorectal-cancer-showcases-clinical-trial-results
Agenus Reports Potential New Treatment for...
06/13/2024 09:18:03

Agenus has published results from a groundbreaking clinical trial in Nature Medicine, revealing the potential of a novel immuno...

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
06/05/2024 12:06:43

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION